Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Primary Myelofibrosis 39Myeloproliferative Disorders 30Leukemia, Myeloid, Acute 23Polycythemia Vera 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Leukemia 17Myelodysplastic Syndromes 15Thrombocythemia, Essential 12Leukemia, Myelogenous, Chronic, BCR-ABL Positive 10Neoplasms 9Multiple Myeloma 9Graft vs Host Disease 9Breast Neoplasms 9Pancreatic Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Recurrence 7Myelodysplastic-Myeloproliferative Diseases 7Lymphoma, Non-Hodgkin 6Leukemia, Lymphocytic, Chronic, B-Cell 6Hematologic Neoplasms 6Prostatic Neoplasms 5Lymphoma, T-Cell 5Lymphoma 5Leukemia, Myeloid, Chronic-Phase 5Hodgkin Disease 5Hematologic Diseases 5Colorectal Neoplasms 5Thrombocytosis 4Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 4Carcinoma, Non-Small-Cell Lung 4

Interventions

Imatinib Mesylate 5venetoclax 1ruxolitinib 1pevonedistat 1nilotinib 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Dasatinib 1Cytarabine 1Cladribine 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Hypereosinophilic Syndrome × ruxolitinib × Clear all
NCT00044304 2026-03-16

Tyrosine Kinase Inhibition to Treat Myeloid Hypereosinophilic Syndrome

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
70 enrolled
Myeloid

Hypereosinophilic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡